ongoing phase

Biotech Stocks With Optimistic Trend – Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

4
Like
Save
Three Highly Unusual Volume Increases: Genocea Biosciences Inc (NASDAQ:GNCA …
www.wallstreetpoint.com

The Healthcare Company on October 7, 2015statedpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save
Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …
www.senecaglobe.com

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
3 Biotech Stocks Getting Some Love -Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

6
Like
Save
Genocea (GNCA) Stock | Shares Trade Higher on Phase 2 Results
www.warriortradingnews.com

Wednesday they announced positive results from an interim study of data collected over a six month period dosing from its ongoing Phase 2 dose optimization trial evaluating their pipeline drug, GEN-003 for the treatment of genital herpes. When …

2
Like
Save
Checklist Early morning Stocks: SBA Communications Corporation (NASDAQ:SBAC …
www.wsnews4investors.com

Genocea Biosciences, Inc. (GNCA reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Pre-market most advance: Genocea Biosciences (NASDAQ:GNCA), Breitburn Energy …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

3
Like
Save
Pre-Open Stock Movers 10/07: (GNCA) (SUNE) (GBX) Higher; (AXPW) (ADXS) (YUM …
www.streetinsider.com

… Inc. (NASDAQ: GNCA) 21.9% HIGHER; announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Vical Reports Second Quarter 2015 Financial Results and Progress in Key …
www.marketwatch.com

In June 2015, Vical announced that its therapeutic vaccines against genital herpes designed to reduce genital lesions and viral shedding in HSV-2 infected patients did not meet the primary endpoint in the ongoing Phase 1/2 study. The bivalent vaccine …

6
Like
Save